search for




 

Comparative Analysis of Lenalidomide versus Thalidomide in Multiple Myeloma; Drug-Induced Peripheral Neuropathy
Yakhak Hoeji 2020;64(6):431-437
Published online December 31, 2020
© 2020 The Pharmaceutical Society of Korea.

So Hee Lee*, Ji Yun Woo*, Shin Yi Hwangbo*, Mi Na Min**, and Ok Youn Han***

*Department of Pharmacy, The Catholic University of Korea, Seoul St. Mary’s Hospital
**Institutional Review Board Administration Team, The Catholic University of Korea, Seoul St. Mary’s Hospital
***Department of Pharmacy, The Catholic University of Korea, Eunpyeong St. Mary’s Hospital
Correspondence to: So Hee Lee, 222 Banpo-daero, Seocho-gu, Seoul 06591, Korea
Tel: +82-2-2258-2569, Fax: +82-2-2258-2565
E-mail: sh1215@cmcnu.or.kr
Received July 21, 2020; Revised November 2, 2020; Accepted December 12, 2020.
Abstract
Lenalidomide (LD) inhibits angiogenesis and exerts immunosuppressive effects. It has been used to treat multiple myeloma and is known to show positive differences in side effects compared to thalidomide (TD). Peripheral neuropathy, one of the most common complications of TD, has been reported to be less frequent with LD treatment. However, no local study has been conducted to compare the incidence of peripheral neuropathy associated with TD and LD administration. Therefore, this study was performed to investigate the appearance, aggravation, or improvement of peripheral neuropathy and the relevant risk factors in patients treated with LD and TD. The electronic medical records of 169 patients with multiple myeloma who had been treated with LD and TD in a tertiary hospital between March 2014 and March 2015 were retrospectively reviewed. There were 85 patients in the LD group and 84 patients in the TD group for the final analysis. An increase in severity of peripheral neuropathy after treatment was observed in 2.4% and 19.1% of patients in the LD and TD groups, respectively (p<0.001). Six patients in the TD group showed two or more increases in grade. In total, 48.2% in the LD group and 10.7% in the TD group (p<0.001) continued chemotherapy without any aggravation of peripheral neuropathy. The patients treated with LD showed less increase in severity of peripheral neuropathy compared with those treated with TD. A significant difference was observed between the groups in the percentage of patients who continued treatment without peripheral neuropathy aggravation.
Keywords : Lenalidomide, thalidomide, adverse drug reaction, peripheral neuropathy


December 2020, 64 (6)
Full Text(PDF) Free

Social Network Service
Services

Cited By Articles
  • CrossRef (0)